Display options
Cite
Vivero M, Bueno R, Chirieac LR. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol. 2017;31(1):122-131doi: 10.1038/modpathol.2017.108.
Vivero, M., Bueno, R., & Chirieac, L. R. (2018). Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 31(1), 122-131. https://doi.org/10.1038/modpathol.2017.108
Vivero, Marina, et al. "Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 31,1 (2018): 122-131. doi: https://doi.org/10.1038/modpathol.2017.108
Vivero M, Bueno R, Chirieac LR. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol. 2018 Jan;31(1):122-131. doi: 10.1038/modpathol.2017.108. Epub 2017 Sep 08. PMID: 28884745; PMCID: PMC6021688.
Copy Download .nbib Format: NLM
Share it on

Mod Pathol. 2018 Jan;31(1):122-131. doi: 10.1038/modpathol.2017.108. Epub 2017 Sep 08.

Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Marina Vivero, Raphael Bueno, Lucian R Chirieac

Affiliations

  1. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  2. Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 28884745 PMCID: PMC6021688 DOI: 10.1038/modpathol.2017.108

Abstract

Pleural diffuse malignant mesothelioma typically presents during the seventh decade of life and has poor prognosis. Recent epidemiologic studies have shown differences between young and older mesothelioma patients, but the biology of pleural mesothelioma in young patients is poorly understood. We studied the clinicopathologic and genetic characteristics in pleural mesothelioma patients aged 35 years and younger. Thirty-six consecutive pleural mesothelioma patients aged 35 years and younger were compared with 48 older patients. We examined demographic and clinical characteristics, histologic type, growth patterns, mitotic index, and nuclear grade on hematoxylin and eosin-stained slides, BAP1 protein expression by immunohistochemistry, and CDKN2A and NF2 deletions by fluorescence in situ hybridization. Clinicopathologic and cytogenetic results were compared between young and older groups, and correlated with overall survival. Young patients were more frequently women, reported less asbestos exposure, and had a greater frequency of prior therapeutic radiation and family history of breast cancer than older patients (P<0.05 each). There were no histologic differences between young and older patients (all P>0.05). CDKN2A deletion was less prevalent in young patients (P=0.01), loss of BAP1 protein expression less frequent in young patients (P=0.06), and NF2 deletion rates similar between groups (P>0.05 each). Median overall survival was 40 vs 26 months (P=0.10) in young and older patients, respectively, and 47 vs 31 months (P=0.04) when comparing patients with epithelioid histology only. High mitotic index and non-epithelioid histology were the only characteristics associated with a poor overall survival in young patients. Young patients with pleural mesothelioma have an equal sex distribution and are more likely to have a history of mantle radiation, family history of breast cancer, and lower rates of CDKN2A deletion than older patients. Our results suggest that pleural mesothelioma in young patients has distinctive clinical and genetic characteristics, despite some similarities to pleural mesothelioma in older patients.

References

  1. Nat Genet. 2011 Jun 05;43(7):668-72 - PubMed
  2. J Clin Oncol. 2013 Dec 20;31(36):4544-9 - PubMed
  3. Nat Genet. 2011 Aug 28;43(10 ):1022-5 - PubMed
  4. Cancer. 1988 Aug 15;62(4):838-47 - PubMed
  5. Oncotarget. 2015 Jun 30;6(18):16766-73 - PubMed
  6. Eur J Cancer Prev. 2008 Nov;17(6):525-34 - PubMed
  7. Cancer. 1990 Mar 15;65(6):1449-55 - PubMed
  8. Lancet. 2001 Feb 10;357(9254):444-5 - PubMed
  9. Cancer. 2009 Aug 25;117(4):247-53 - PubMed
  10. Cancer. 1972 Nov;30(5):1216-8 - PubMed
  11. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 - PubMed
  12. Cancer Res. 2006 Mar 15;66(6):2970-9 - PubMed
  13. Histopathology. 2008 Jun;52(7):824-30 - PubMed
  14. Cancer. 2007 Apr 1;109(7):1432-8 - PubMed
  15. Eur J Cardiothorac Surg. 2011 Aug;40(2):298-303 - PubMed
  16. Clin Cancer Res. 2003 Jun;9(6):2108-13 - PubMed
  17. Ann Occup Hyg. 2001 Oct;45(7):519-23 - PubMed
  18. Carcinogenesis. 2015 Jan;36(1):76-81 - PubMed
  19. Thorax. 1983 Oct;38(10):744-6 - PubMed
  20. Mod Pathol. 2012 Feb;25(2):260-71 - PubMed
  21. Chest. 2007 Feb;131(2):376-82 - PubMed
  22. Virchows Arch. 2008 Dec;453(6):627-35 - PubMed
  23. JCI Insight. 2016 Nov 17;1(19):e87062 - PubMed
  24. Bull World Health Organ. 2011 Oct 1;89(10):716-24, 724A-724C - PubMed
  25. Genet Med. 2016 Jul;18(7):712-9 - PubMed
  26. Anticancer Res. 2005 Sep-Oct;25(5):3671-6 - PubMed
  27. Mod Pathol. 2008 Jun;21(6):742-7 - PubMed
  28. J Clin Oncol. 1988 Jan;6(1):147-53 - PubMed
  29. J Cell Physiol. 1999 Aug;180(2):150-7 - PubMed
  30. Occup Environ Med. 1994 Dec;51(12):804-11 - PubMed
  31. Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 - PubMed
  32. Cancer Biol Ther. 2016;17 (3):328-35 - PubMed
  33. Occup Environ Med. 1995 Nov;52(11):775-7 - PubMed
  34. Nucleic Acids Res. 2015 Feb 18;43(3):e19 - PubMed
  35. Cancer Sci. 2012 May;103(5):868-74 - PubMed
  36. Int J Cancer. 1988 Apr 15;41(4):525-30 - PubMed
  37. Med Pediatr Oncol. 1981;9(4):367-73 - PubMed
  38. J Thorac Oncol. 2013 Nov;8(11):1430-3 - PubMed
  39. Nat Biotechnol. 2013 Mar;31(3):213-9 - PubMed

Substances

MeSH terms

Publication Types

Grant support